{"entity":{"id":"nct06265025","kind":"trial","name":"GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in melanoma and colorectal cancer, run by GeneMedicine Co., Ltd., now recruiting.","summary":"GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06265025 by GeneMedicine Co., Ltd., with 125 participants planned, started 2024-02-20 and due to reach its primary completion in 2025-05-30. Interventions recorded: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C). Conditions listed: Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06265025","url":"https://clinicaltrials.gov/study/NCT06265025"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","colorectal","rcc","cervical"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06265025","phase":"1/2","setting":"A Phase I/II, Open-label, Dose-escalation With Expansion Study of GM103 Via Intratumoral Injection, Alone and in Combination With Pembrolizumab in Adult Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors","sponsor":"GeneMedicine Co., Ltd.","participation":[{"nct":"NCT06265025","source":"https://clinicaltrials.gov/study/NCT06265025","fetchedAt":"2026-10-07T16:54:29.928Z","studySha256":"8a59816aa509813651372cb6e136bdc5d9f4ac714974bb4b9f92a15be9047ce7","overallStatus":"RECRUITING","lastUpdatePosted":"2024-03-21","leadSponsor":"GeneMedicine Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":125,"enrolmentType":"ESTIMATED","siteCount":4,"recruitingSiteCount":1,"countries":["South Korea"]}],"started":"2024-02-20","startedType":"actual","enrolled":125,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06265025/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}